Anti–platelet factor 4 testing for heparin-induced thrombocytopenia: Assessing the indication for its use for quality improvement as a patient safety measure
Anti–platelet factor 4 testing for heparin-induced thrombocytopenia: Bewertung der Indikation für den Einsatz als Qualitätsverbesserung zur Patientensicherheit
American Journal of Clinical Pathology · 19.11.2025 · 164 (5) · 778-784
DOI: 10.1093/ajcp/aqaf102 ↗Auf einen Blick
Bei 261 PF4/PVS-ELISA-Tests war fast die Hälfte bei niedriger 4T-Wahrscheinlichkeit durchgeführt. Die Testpositivität unterschied sich zwischen den Gruppen nicht signifikant.
Fragestellung
Wie angemessen ist die Anordnung von PF4-Tests bei Verdacht auf HIT anhand des 4T-Scores?
Methode
Retrospektive Analyse von 261 PF4/PVS-ELISA-Tests bei 261 Patient:innen von Januar 2020 bis Juni 2022; Vergleich von 4T <4 und 4T ≥4.
Ergebnisse
136/261 Tests (52,11 %) waren bei 4T ≥4 indiziert, 125/261 (47,89 %) bei 4T <4. Positivität: 11,03 % vs. 5,6 %; P = .125. 22 positive Tests, 10 mit SRA, 2 SRA-positiv.
Schlussfolgerung der Autor:innen
Die meisten HIT-Tests entsprachen nicht den Empfehlungen der American Society of Hematology. Übertestung kann unnötige Antikoagulation begünstigen, Unterbehandlung könnte in Hochrisikofällen aufgetreten sein.
Kernaussagen
- 47,89 % der Tests erfolgten bei 4T <4
- Positivität des PF4/PVS-ELISA unterschied sich nicht signifikant
- 75,20 % der Low-risk-Patient:innen setzten Heparin ab
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 17.09.2025. Verfasst von Hisham F Bahmad und 10 weiteren Autor:innen. Beteiligte Einrichtung: Arkadi M. Rywlin, MD, Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL, United States. Hauptthemen laut MEDLINE: Thrombocytopenia, Heparin, Platelet Factor 4, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Objective
To assess the appropriateness and clinical indication of ordering the heparin-induced thrombocytopenia (HIT) platelet factor 4 (PF4) tests (based on the 4T score) for the diagnosis of HIT.
Methods
We retrospectively analyzed 261 PF4/polyvinylsulfonate (PVS)–enzyme-linked immunosorbent assay (ELISA) tests performed for 261 patients between January 2020 and June 2022. Patients were divided into 2 groups: 4T score less than 4 (unindicated HIT test requests) and 4T score of 4 or more (appropriately indicated HIT test requests). Clinical characteristics, test results, and treatment decisions were compared between groups.
Results
Only 136 (52.11%) of 261 tests were indicated by a 4T score or 4 or higher, whereas 125 (47.89%) of 261 tests were performed in low-probability patients (4T score <4). The PF4/PVS-ELISA positivity rate did not differ significantly between groups (11.03% vs 5.6%, P = .125). Patients with indicated testing had higher baseline platelet counts, longer time to platelet drop, and a greater percent drop in platelets (all P < .001). Among the 22 PF4/PVS-ELISA positive cases, only 10 had serotonin release assay (SRA) testing performed, of which 2 were SRA-positive. Among patients with low clinical probability, 75.20% (94/125) had heparin discontinued, despite the minimal risk.
Conclusions
Most HIT testing was inconsistent with guideline recommendations of the American Society of Hematology. Overtesting may lead to unnecessary anticoagulation, and undertreatment may have occurred in high-risk cases. These findings underscore the need for improved implementation of 4T-based decision tools to guide HIT evaluation and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arkadi M. Rywlin, MD, Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL, United States.
- Department of Pathology, Albany Medical Center, Albany, NY, United States.
- Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, United States.
- Department of Pathology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, United States.
ORCID-Profile: Hisham F Bahmad, Richard R Pacheco
Zitieren
APA
Bahmad, H. F., Delgado, R., Pacheco, R. R., Oh, K. S., Rojas Gomez, L. P., Vallabhaneni, E., Azimi, R., Sriganeshan, V., Howard, L., Poppiti, R., & Alghamdi, S. (2025). Anti–platelet factor 4 testing for heparin-induced thrombocytopenia: Assessing the indication for its use for quality improvement as a patient safety measure. American Journal of Clinical Pathology, 164(5), 778-784. https://doi.org/10.1093/ajcp/aqaf102
Vancouver
Bahmad HF, Delgado R, Pacheco RR, Oh KS, Rojas Gomez LP, Vallabhaneni E, et al. Anti–platelet factor 4 testing for heparin-induced thrombocytopenia: Assessing the indication for its use for quality improvement as a patient safety measure. American Journal of Clinical Pathology. 2025;164(5):778-784. doi:10.1093/ajcp/aqaf102
BibTeX
@article{Bahmad2025,
author = {Bahmad, Hisham F and Delgado, Ruben and Pacheco, Richard R and Oh, Kei Shing and Rojas Gomez, Lorena P and Vallabhaneni, Esha and Azimi, Roshanak and Sriganeshan, Vathany and Howard, Lydia and Poppiti, Robert and Alghamdi, Sarah},
title = {Anti–platelet factor 4 testing for heparin-induced thrombocytopenia: Assessing the indication for its use for quality improvement as a patient safety measure},
journal = {American Journal of Clinical Pathology},
year = {2025},
volume = {164},
number = {5},
pages = {778--784},
doi = {10.1093/ajcp/aqaf102}
}
EUVIMED